(CKPT) – Company Press Releases
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm
-
CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
-
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm
-
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT)
-
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
-
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
-
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
-
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
-
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
-
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
-
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
-
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
-
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
-
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
-
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
-
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
-
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
-
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
-
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
-
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
-
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
-
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
-
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Checkpoint Therapeutics Announces Reverse Stock Split
-
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
-
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
-
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
-
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
-
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
-
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Back to CKPT Stock Lookup
